These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 118112)

  • 1. Human serum inhibits the interaction between C1q or rheumatoid factor and IgG-coated latex particles. Reduction of these C1-dependent properties after complement activation in vitro and in vivo.
    Hällgren R
    Immunology; 1979 Nov; 38(3):529-37. PubMed ID: 118112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic measurement of the interaction of rheumatoid factor with IgG-coated latex particles and the influence of the first component of human complement.
    Hällgren R
    Clin Exp Immunol; 1980 Jan; 39(1):154-63. PubMed ID: 6771071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic studies of the association of complement components and IgG-coated latex particles incubated in normal or complement-activated human serum.
    Hällgren R
    Clin Exp Immunol; 1981 Apr; 44(1):191-200. PubMed ID: 7261475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of the agglutination of IgG-coated latex particles by C1q: the influence of heat-labile serum components.
    Hällgren R; Stålenheim G; Venge P
    Scand J Immunol; 1979; 9(4):365-72. PubMed ID: 441683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1q-latex assay for immune complexes. Complexes that react with both C1q and monoclonal rheumatoid factor in lupus erythematosus and lung cancer.
    Medof ME
    J Lab Clin Med; 1982 May; 99(5):678-92. PubMed ID: 6978370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.
    Doekes G; Schouten J; Cats A; Daha MR
    Immunology; 1985 Jul; 55(3):555-64. PubMed ID: 4018839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic studies of phagocytosis. III. The complement-dependent opsonic and anti-opsonic effects of normal and sle sera.
    Håkansson L; Hällgren R; Venge P
    Immunology; 1982 Sep; 47(1):91-9. PubMed ID: 6981589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Quantitative laser-nephelometric detection of rheumatoid factor, using IgG coated latex particles (author's transl)].
    Husmann K; Lakomek HJ; Richter O; Jacobi E; Krüskemper HL
    J Clin Chem Clin Biochem; 1981 Nov; 19(11):1125-30. PubMed ID: 7310334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryoglobulinemia induced by monoclonal immunoglobulin G rheumatoid factors derived from autoimmune MRL/MpJ-lpr/lpr mice.
    Gyotoku Y; Abdelmoula M; Spertini F; Izui S; Lambert PH
    J Immunol; 1987 Jun; 138(11):3785-92. PubMed ID: 3495570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of immune complexes in idiopathic thrombopenia].
    Bragiel I; Walewska I
    Acta Haematol Pol; 1980; 11(4):267-74. PubMed ID: 7293689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological diagnosis of rheumatoid arthritis and systemic lupus erythematosus.
    Wager O
    Ann Clin Res; 1975 Jun; 7(3):168-82. PubMed ID: 1103712
    [No Abstract]   [Full Text] [Related]  

  • 12. The relationship between the binding ability and the rate of activation of the complement component C1.
    Folkerd EJ; Gardner B; Hughes-Jones NC
    Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies with rabbit IgG-coated latex for the detection of rheumatoid factor.
    Cheng CT; Persellin RH
    J Med; 1973; 4(2):88-95. PubMed ID: 4127137
    [No Abstract]   [Full Text] [Related]  

  • 14. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB; Sjöholm AG
    Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.
    Heinz HP; Burger R; Golan MD; Loos M
    J Immunol; 1984 Feb; 132(2):804-8. PubMed ID: 6606678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential precipitation of the Clq subcomponent of the first complement component (C1) by polyethylene glycol from normal human serum and sera of patients with collagen diseases.
    Van Dijk H; Van Voorst J; Jankowski IG; Imhof JW; Kerckhaert JA
    Clin Exp Immunol; 1984 Aug; 57(2):495-501. PubMed ID: 6432386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification and characterization of the 1q subcomponent of canine complement and its use in the 125I-C1q binding assay for detection of immune complexes.
    Wu CC; Bey RF; Loken KI
    Am J Vet Res; 1988 Jun; 49(6):865-9. PubMed ID: 3135770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activating properties of complexes containing rheumatoid factor in synovial fluids and sera from patients with rheumatoid arthritis.
    Elson CJ; Carter SD; Cottrell BJ; Scott DG; Bacon PA; Wallington TB
    Clin Exp Immunol; 1985 Feb; 59(2):285-92. PubMed ID: 3978872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction.
    Sjöwall C; Wetterö J; Bengtsson T; Askendal A; Almroth G; Skogh T; Tengvall P
    Biochem Biophys Res Commun; 2007 Jan; 352(1):251-8. PubMed ID: 17113035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
    Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
    J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.